Heinz Lubenau

Heinz Lubenau

Company: VAXIMM

Job title: Chief Executive Officer


Oral DNA Vaccination in Combination With Checkpoint Inhibitor In Recurrent Glioblastoma 5:15 pm

Cytotoxic T-cell approach targeting VEGFR-2 on tumor vasculature and tumor cells Combination with checkpoint inhibitors Intratumoral immune-biomarkers pre- and post treatmentRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.